Subscribe to out newsletter today to receive latest news administrate cost effective for tactical data.
Medical Program OverviewThis comprehensive medical package includes one full cycle of Lutetium-177 PSMA radioligand therapy for advanced prostate cancer, combined with Ga-68 PSMA PET/CT imaging. The therapy is performed at the renowned Helios Klinikum Berlin-Buch, one of Germany’s leading academic hospitals, internationally recognized for its expertise in oncology and nuclear medicine.
Lutetium-177 PSMA therapy is a highly targeted, personalized treatment designed for patients with metastatic castration-resistant prostate cancer (mCRPC) that expresses PSMA (Prostate-Specific Membrane Antigen). This advanced therapy delivers radiation directly to cancer cells, minimizing damage to surrounding healthy tissue.
This comprehensive medical package includes one full cycle of Lutetium-177 PSMA radioligand therapy for advanced prostate cancer, combined with Ga-68 PSMA PET/CT imaging. The therapy is performed at the renowned Helios Klinikum Berlin-Buch, one of Germany’s leading academic hospitals, internationally recognized for its expertise in oncology and nuclear medicine.
Lutetium-177 PSMA therapy is a highly targeted, personalized treatment designed for patients with metastatic castration-resistant prostate cancer (mCRPC) that expresses PSMA (Prostate-Specific Membrane Antigen). This advanced therapy delivers radiation directly to cancer cells, minimizing damage to surrounding healthy tissue.
Approx. 45–50 minutes from Leading Center for Oncology & Nuclear Medicine in Germany
Located in the northern part of Berlin, Helios Klinikum Berlin-Buch is one of Germany’s most advanced academic hospitals, renowned for its excellence in oncology, radiology, and nuclear medicine. As part of the Helios Health Group—the largest private hospital network in Europe—it combines cutting-edge medical technology with top-tier specialists and research-driven care.
The clinic is affiliated with the Charité University Hospital and participates in international clinical studies, making it a center of innovation for cancer therapies, including Lutetium-177 PSMA radioligand therapy for advanced prostate cancer.
Helios Klinikum Berlin-Buch is a leading academic hospital in Berlin, recognized for its commitment to high-quality patient care and medical excellence. The hospital holds several prestigious certifications and accreditations, underscoring its status as a top-tier medical institution:
These certifications and accreditations affirm Helios Klinikum Berlin-Buch’s dedication to providing exceptional medical care and its leadership in specialized treatments.
Education and Academic Background• 1984–1991: Studied Medicine at Ludwig Maximilian University (LMU), Munich, Germany
• 1993: Doctorate in Medicine (Dr. med.)
• 1996: Board certification in Nuclear Medicine
• 2001: Habilitation (post-doctoral qualification) and teaching license in Nuclear Medicine
• 2007: Appointed Associate Professor at LMU Munich
Clinical and Research Career• 1992–1994: Research Assistant, Department of Radiology, LMU Munich
• 1994–1995: Research Assistant, Department of Nuclear Medicine, LMU Munich
• 1995: Research Assistant, Institute of Radiological Diagnostics (MRI division), LMU Munich
• 1996: Senior Physician, Department of Nuclear Medicine, LMU Munich
• 1996–1998: Research Fellow at the Department of Radiology, University of Pennsylvania, Philadelphia, USA
• 1998–2004: Senior Physician, Department of Nuclear Medicine, LMU Munich
• Since 2004: Chief Physician, Department of Nuclear Medicine, Helios Klinikum Berlin-Buch
◦ Also Head of the Nuclear Medicine Unit at the Robert-Rössle Cancer Center, Berlin-Buch
• Since 2008: Head of Medical Imaging Services (Nuclear Medicine, Radiology, and Radiation Therapy)
Specializations and Clinical Focus• Lu-177-PSMA Radioligand Therapy for advanced prostate cancer
• Radioreceptor Therapy for neuroendocrine tumors using 177Lu-DOTATOC
• PET/CT Imaging using tracers like F-18 FDG, Ga-68 PSMA, and Ga-68 DOTATOC
• SIRT (Selective Internal Radiation Therapy) for liver tumors and metastases
•Diagnosis and treatment of thyroid disorders
Memberships and Editorial Roles•Member, Society of Nuclear Medicine (SNM)
•Member, European Association of Nuclear Medicine (EANM)
•Member, German Society of Nuclear Medicine (DGN)
•Board Member, PET e.V., Association for the Advancement of PET Imaging
•Editor of the journal “Angewandte Nuklearmedizin” (Applied Nuclear Medicine), Thieme Publishing
Prof. Dresel is a globally recognized expert in nuclear medicine with more than three decades of clinical and academic experience. He has played a key role in the development and implementation of Lu-177 PSMA therapy, a cutting-edge treatment for metastatic castration-resistant prostate cancer.
Full Medical Program – Step-by-StepLutetium-177 PSMA Therapy for Prostate Cancer
+ Ga-68 PSMA PET/CT Imaging
Supervising Physician: Prof. Dr. med. Stefan Dresel
Location: Department of Nuclear Medicine, Helios Klinikum Berlin-Buch
Diagnostic & Laboratory Testing for Lutetium-177 PSMA Therapy
To ensure that you’re a suitable candidate for Lutetium-177 PSMA treatment, we conduct a series of diagnostic tests:
Establish baseline levels of tumor activity
Evaluate your blood health for safe treatment
PSMA PET/CT Imaging for Prostate Cancer
A Gallium-68 PSMA PET/CT scan is crucial for precise tumor identification and therapy planning:
Kidney Function Scintigraphy for Safe Therapy
A renal scan ensures safe Lutetium-177 therapy administration:
Tailored Lutetium-177 PSMA Dose Preparation
Your Lutetium-177 dose is customized based on:
Lutetium-177 PSMA Therapy Administration
During a 4-5 day inpatient stay in our Radionuclide Therapy Unit:
Post-Therapy Monitoring & Evaluation
Our team conducts follow-up whole-body scintigraphy 24–48 hours after treatment to monitor the biodistribution and effectiveness of Lutetium-177 therapy. You will receive a personalized follow-up plan to ensure continued progress.
Discharge and Long-Term Monitoring
After completing your therapy, we provide:
Possible Additional Lutetium-177 Cycles
If necessary, additional cycles of Lutetium-177 PSMA therapy may be recommended, typically at 6–8 week intervals, based on PSA levels and response to treatment.
WEGOVITA’s 8 Golden StepsHelios Klinikum Berlin-Buch | Full-Service International Patient Coordination
Medical File Review & Pre-ApprovalBefore confirming the treatment journey, your medical records are reviewed by Prof. Dr. med. Stefan Dresel and his team at Helios Klinikum Berlin-Buch.
This ensures you meet the key criteria for Lutetium-177 therapy and avoids unnecessary travel or delays.
WEGOVITA assists you in collecting and organizing all necessary documents (scans, lab results, oncologist notes, etc.) in the correct format for medical evaluation.
Review & ConfirmationOnce pre-approval is granted, you will receive your customized treatment plan and cost estimate.
Confirm your intention to proceed via email or WhatsApp to begin the formal process.
Contract & PaymentReceive the official treatment contract and detailed invoice from WEGOVITA.
Sign and return the agreement.
Submit the deposit or full payment and share the payment confirmation.
Visa & Travel SupportWEGOVITA provides an official visa invitation letter if required.
We assist with embassy procedures and documentation.
Travel timeline and flight coordination are handled in line with your therapy schedule.
Accommodation & Airport TransfersWe arrange a hotel near Helios Klinikum for your comfort and accessibility.
Private airport pickup with a name sign is included.
All local transportation to the hospital is pre-arranged and coordinated by our team.
Hospital Admission & Medical CoordinationYour personal WEGOVITA coordinator will accompany you to all hospital appointments.
Support is provided during registration, lab work, scans, consultations, and therapy days.
Daily communication and real-time updates from your medical team are ensured.
Language & Concierge SupportProfessional medical interpreter (up to 18 hours/day) is available on-site.
All consultations, procedures, and discharge meetings are supported in your language.
Additional concierge services are offered to meet your daily comfort and logistical needs.
Discharge & Follow-Up CareYou receive translated discharge summaries, medical imaging, and lab results.
WEGOVITA prepares a follow-up plan and coordinates any further cycles of therapy if needed.
We continue to support you after your return, including telemedicine check-ins and communication with your home oncologist.
WEGOVITA offers medical coordination services by connecting international patients with top hospitals and specialists across Germany. We support access to expert evaluations, facilitate treatment logistics, and present a range of available medical options.
However, WEGOVITA does not provide direct medical treatment, make medical diagnoses, or recommend specific therapies. All final medical decisions—including diagnosis, treatment planning, and cost—are made solely by licensed medical professionals after a full clinical assessment of the individual patient.
This information is provided for informational purposes, based on internationally recognized guidelines and practices used in Germany’s leading medical institutions. It is not a substitute for professional medical advice.
💡 Interested in clinical trial references, treatment innovations, or cost comparisons? Contact our medical coordination team at info@wegovita.com for personalized assistance.
Your Health. Your Journey. With WEGOVITA.